Last reviewed · How we verify
Kaftrio
At a glance
| Generic name | Kaftrio |
|---|---|
| Also known as | Trikafta |
| Sponsor | Royal College of Surgeons, Ireland |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
- Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor (NA)
- TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era
- Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis
- Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (PHASE4)
- Renal Impact of KAFTRIO in Mucoviscidose Population
- Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kaftrio CI brief — competitive landscape report
- Kaftrio updates RSS · CI watch RSS
- Royal College of Surgeons, Ireland portfolio CI